Ventyx Biosciences, Inc. (NASDAQ:VTYX) Receives $14.00 Average PT from Analysts

Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) have received a consensus rating of “Reduce” from the nine ratings firms that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating and eight have issued a hold rating on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $14.00.

A number of equities research analysts have weighed in on VTYX shares. Lifesci Capital restated a “market perform” rating and issued a $14.00 price objective on shares of Ventyx Biosciences in a report on Thursday, January 8th. UBS Group reiterated a “neutral” rating and set a $14.00 target price (down from $20.00) on shares of Ventyx Biosciences in a report on Thursday, January 8th. Wells Fargo & Company reissued an “equal weight” rating and issued a $14.00 price target on shares of Ventyx Biosciences in a research report on Thursday, January 8th. Clear Str downgraded Ventyx Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, January 7th. Finally, Oppenheimer lowered Ventyx Biosciences from an “outperform” rating to a “market perform” rating in a research report on Thursday, January 8th.

Ventyx Biosciences Price Performance

Shares of Ventyx Biosciences stock opened at $14.00 on Thursday. Ventyx Biosciences has a 1 year low of $0.78 and a 1 year high of $25.00. The firm has a market cap of $1.00 billion, a price-to-earnings ratio of -9.33 and a beta of 1.26. The company has a 50-day moving average of $13.74 and a 200 day moving average of $8.85.

Insider Buying and Selling at Ventyx Biosciences

In other news, insider John Nuss sold 12,675 shares of Ventyx Biosciences stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $7.72, for a total value of $97,851.00. Following the completion of the transaction, the insider owned 489,481 shares of the company’s stock, valued at $3,778,793.32. The trade was a 2.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Raju Mohan sold 47,345 shares of the company’s stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $7.72, for a total transaction of $365,503.40. Following the completion of the transaction, the chief executive officer owned 2,372,863 shares in the company, valued at approximately $18,318,502.36. The trade was a 1.96% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 14.49% of the company’s stock.

Institutional Trading of Ventyx Biosciences

Several institutional investors have recently bought and sold shares of the company. Virtus Investment Advisers LLC purchased a new position in Ventyx Biosciences in the fourth quarter worth about $293,000. Wellington Management Group LLP purchased a new stake in shares of Ventyx Biosciences during the fourth quarter valued at approximately $2,052,000. Squadron Capital Management LLC purchased a new stake in shares of Ventyx Biosciences during the fourth quarter valued at approximately $3,702,000. Tudor Investment Corp ET AL bought a new stake in shares of Ventyx Biosciences during the fourth quarter valued at approximately $5,270,000. Finally, Quadrature Capital Ltd bought a new stake in shares of Ventyx Biosciences during the fourth quarter valued at approximately $284,000. 97.88% of the stock is owned by hedge funds and other institutional investors.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.